You are here

P&T January 2015

Features

Cost and Access Are Often at Odds; Enrollees Are Caught in the Middle

Confusion over which physicians, facilities, and pharmacies are in insurance companies’ networks has become an issue among enrollees in marketplace plans under health care reform, Medicare Advantage plans, and even accountable care organizations.

Once-daily, single-tablet regimens have become integral to the management of human immunodeficiency virus type 1 infection, partly because they may improve adherence due to a lower pill burden. This article reviews the single-tablet options.

When specially trained pharmacy technicians took patients’ medication histories in a hospital emergency department, the histories they conducted were accurate 88% of the time compared with 57% of those conducted by nurses, who had other duties.
Nonadherence contributes to poor attainment of treatment goals in type-2 diabetes mellitus; drug tolerability may play a part. Colesevelam, a second-generation bile acid resin, has improved tolerability and is associated with reductions in hemoglobin A1c.
Meeting Highlights

Among the featured topics: oncolytic immunotherapy, BRAF/MEK inhibition, and a programmed death-1 inhibitor at the Society for Melanoma Research.

Meeting Highlights

Among the featured topics: anti­coagulation therapy, an alternative to statins, and endocarditis in the absence of dental antibiotic prophylaxis at the American Heart Association Scientific Sessions.

Departments

Medication Errors
Multiple latent failures align to harm a patient seriously.
Prescription: Washington
Hospitals can collect leftover narcotics—but will they?

FDA approvals, drug indications, and updates

Meningococcal group B vaccine (Trumenba) to prevent more types of invasive meningococcal disease; antihemophilic factor (recombinant), porcine sequence (Obizur) to treat bleeding from acquired hemophilia A; and pirfenidone (Esbriet) and nintedanib (Ofev) for idiopathic pulmonary fibrosis

Letter to the Editor
Drug Forecast
Vortioxetine (Brintellix): a new serotonergic antidepressant